Skip to Main Content

Author Details

Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
2008
33
19
PMIDPaper TitleJournal TitlePublished Year
36355448Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.Cancer Discov2023
37581927RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition.J Clin Invest2023
36971438Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells.J Vis Exp2023
36856575Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy.Cancer Discov2023
35681175Integrated multiomic approach for identification of novel immunotherapeutic targets in AML.Biomark Res2022
35532363The Cell Type-Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia.Blood Cancer Discov2022
33473139The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells.Nat Commun2021
34407958Clonal Hematopoiesis: From Mechanisms to Clinical Intervention.Cancer Discov2021
31480965Asparaginase activities during intensified treatment with pegylated <i>E. coli</i> asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia.Leuk Lymphoma2020
31895700Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.J Clin Invest2020
33123685Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.Nat Cancer2020
32153780Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.Clin Transl Immunology2020
32150611Single-cell mutational profiling enhances the clinical evaluation of AML MRD.Blood Adv2020
30728456Data mining for mutation-specific targets in acute myeloid leukemia.Leukemia2019
29946192Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.Leukemia2019
31100828A Role for Lipid Mediators in Acute Myeloid Leukemia.Int J Mol Sci2019
30948486Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.Haematologica2019
29472724Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.Leukemia2018
29896056The high-intensity reflectometer of the Jülich Centre for Neutron Science: MARIA.J Appl Crystallogr2018
28743264Recent developments in immunotherapy of acute myeloid leukemia.J Hematol Oncol2017
28415689Targeting CD157 in AML using a novel, Fc-engineered antibody construct.Oncotarget2017
29249818Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.Leukemia2017
28832948Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.Br J Haematol2017
26239198Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.Leukemia2016
28060296Studying Soft-matter and Biological Systems over a Wide Length-scale from Nanometer and Micrometer Sizes at the Small-angle Neutron Diffractometer KWS-2.J Vis Exp2016
24912430Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.Leukemia2015
26449653Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.J Hematol Oncol2015
26055139Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings.Ann Hematol2015
26111468Immunotherapy for Acute Myeloid Leukemia.Semin Hematol2015
24300852CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Blood2014
24816240Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Haematologica2014
24083240Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators.Biomed Res Int2013
18832028Reduction of inflammation and chronic tissue damage by omega-3 fatty acids in fat-1 transgenic mice with pancreatitis.Biochim Biophys Acta2008
  • 1 - 33 of 33

Recommended Authors

Leo Ruhnke
University Hospital Dresden
Career Start Year 2018
Number of shared co-authors 3
Heidi Altmann
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2017
Number of shared co-authors 3
Adam J Lamble
Seattle Children's Hospital, University of Washington
Career Start Year 2017
Number of shared co-authors 2
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Career Start Year 2014
Number of shared co-authors 6
Uma Borate
The Ohio State University
Career Start Year 2008
Number of shared co-authors 7
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 3
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Kara L Davis
Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 3
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 4
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 0
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 4
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 0
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 6
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 8
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 6
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 1
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Career Start Year 2004
Number of shared co-authors 0
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 8
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 4
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 0
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 6
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 4
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 5
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 1
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 1
Michael Dworzak
St. Anna Children's Cancer Research Institute (CCRI)
Career Start Year 1990
Number of shared co-authors 0
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 6
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 6
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Career Start Year 1984
Number of shared co-authors 1
Paul Brent Ferrell
Vanderbilt University
Career Start Year 1981
Number of shared co-authors 0

Collaborators

Ravindra Majeti
Stanford University School of Medicine
Co-authored papers 11
Melissa Stafford
Ulster University
Co-authored papers 6
Yusuke Nakauchi
Institute of Space and Astronautical Science
Co-authored papers 5
M Ryan Corces
Gladstone Institute of Neurological Disease
Co-authored papers 2
Wolfgang E Berdel
University Hospital Munster
Co-authored papers 2
Rozario Thomas
Memorial Sloan Kettering Cancer Center (MSKCC)
Co-authored papers 1
Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Co-authored papers 1
Samuel Levy
Bluestar Genomics Inc.
Co-authored papers 1
Erin McCarthy
Bluestar Genomics Inc.
Co-authored papers 1
Purvesh Khatri
University of California San Francisco
Co-authored papers 1
Tierney Phillips
Bluestar Genomics Inc.
Co-authored papers 1
Matthew H Porteus
Stanford University
Co-authored papers 1
Andrew J Gentles
Stanford Center for Biomedical Informatics Research, Stanford University
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Bruno C Medeiros
AbbVie Inc.
Co-authored papers 1
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 1
Release 1.2